LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma
Our findings establish substantial evidence for LMO2 as both a potential therapeutic candidate in cancer immunotherapy and a significant prognostic modulator in ccRCC pathogenesis. The mechanistic characterization of LMO2's tumor-suppressive functions warrants heightened translational consideration in both clinical management strategies and molecular etiology research.
Authors
- Xiaoli Zhao (ORCID: https://orcid.org/0009-0002-1276-5134)
- Zhansheng Zhu (ORCID: https://orcid.org/0000-0002-8313-0964)
- Xuemei Yang (ORCID: https://orcid.org/0000-0003-4005-978X)
- Renren Li (ORCID: https://orcid.org/0000-0003-3781-9848)
- Mengmeng Li (ORCID: https://orcid.org/0000-0003-1117-8106)
- Cong Wang (ORCID: https://orcid.org/0000-0002-2184-6879)
- Jia Wei (ORCID: https://orcid.org/0000-0002-9634-9439)
- Huiping Wang (ORCID: https://orcid.org/0000-0003-1803-1801)
Institutions
- Xuzhou Medical College (CN)
- Xuzhou No.1 People's Hospital (CN)
- Maternal and Child Health Hospital of Xuzhou (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1016/j.tranon.2025.102409
- Citations
- 2
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.04